Steve Harr, See Remarks at Juno Therapeutics, Inc. (JUNO), sold 59,057 shares at $39.21 ($2.2M) on 2016-03-01, disclosed to the SEC on 2016-03-02.
Open-market sale of $2.2M JUNO by See Remarks. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.06 | 2,013 | $71K | 3.2% |
| 2 | $35.06 | 2,013 | $71K | 3.2% |
| 3 | $36.20 | 10,581 | $383K | 17.3% |
| 4 | $36.20 | 10,581 | $383K | 17.3% |
| 5 | $36.82 | 900 | $33K | 1.5% |
| 6 | $38.18 | 6,387 |
| $244K |
| 11.0% |
| 7 | $38.18 | 6,387 | $244K | 11.0% |
| 8 | $39.21 | 10,076 | $395K | 17.8% |
| 9 | $39.21 | 10,076 | $395K | 17.8% |
| 10 | $39.88 | 43 | $2K | 0.1% |
| Total | $37.59 avg | 59,057 | $2.2M | 100% |
| Filing → |
| JUNO | SELL | 2017-06-29 | $263K | — | Filing → |
| JUNO | SELL | 2016-06-13 | $2.6M | — | Filing → |
| JUNO | SELL | 2016-03-04 | $225K | — | Filing → |